Cambridge-based diagnostics company Tagomics has secured an £860,000 ($1.1 million) grant from Innovate UK to develop an early-stage colorectal cancer (CRC) diagnostic using its Interlace platform. The award, part of the UK government’s Biomedical Catalyst programme, supports a £1.2 million project focused on identifying DNA-based biomarkers through multiomic profiling.
The pilot study—led by Dr. Arash Assadsangabi, gastroenterologist at Salford Royal NHS Foundation Trust—will profile 250 patients suspected of CRC in partnership with the Northern Care Alliance Research Collection. The aim is to validate early biomarkers and prove Interlace’s value in noninvasive detection.